Your present location:HOME > Biosimilars
●  First biological product launched in 1999   ●  3 products launched, 2 have the largest market share in China   ●  Focusing on research and commercialization of recombinant protein drugs      from prokaryotic expression and mammalian cell expression   ●  Robust pipeline comprising biosimilars and innovative biologics   ●  Manufacturing facilities complying with cGMP requirements   ●  Dosage forms: ampoules, vials, pre-filled syringes, etc   Qilu Biopharmaceutical Industrial Park      ●  Total construction area covers 800,000 m2
●  Being constructed in accordance with the requirements of USFDA cGMP/EU GMP

●  Phase I construction completed and manufacture commenced. Manufacturing facilities are available for production of:
     - Mammalian cell expression products
   - Prokaryotic cell expression products
   - Small molecule finished formulations